Grist E, Dutey-Magni P, Parry MA, Mendes L, Sachdeva A, Proudfoot JA, Hamid AA, Ismail M, Howlett S, Friedrich S, DePaula Oliveira L, Murphy L, Brawley C, Dairo O, Lall S, Liu Y, Wetterskog D, Wingate A, Nowakowska K, Zakka L, Amos CL, Atako NB, Wang V, Rush HL, Jones RJ et al. (2025)
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Cell (in press)
DOI 10.1016/j.cell.2025.07.042, PubMed 40865526

Liukaityte R, Stenberg VY, Kleinauskas A, Juzenas P, Urbanucci A, Juzeniene A (2025)
Combination of PSMA targeting alpha-emitting radioligand [²¹²Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models
Med Oncol, 42 (8), 362
DOI 10.1007/s12032-025-02925-9, PubMed 40694184

Severson TM, Minnee E, Zhu Y, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Menezes R, Gregoricchio S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden MS, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A et al. (2025)
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer
Cell Rep Med, 6 (7), 102215
DOI 10.1016/j.xcrm.2025.102215, PubMed 40609538